Abstract

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).
Noam Falbel Ponde ... Christian Jackisch
Journal of Clinical Oncology | VOL. 37
Noam Falbel Ponde, et. al.Noam Falbel Ponde ... Christian Jackisch
20 May 2019
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Noam Pondé ... Dominique Agbor-Tarh
Breast cancer research and treatment | VOL. 185
Noam Pondé, et. al.Noam Pondé ... Dominique Agbor-Tarh
19 Sep 2020
Cardiac toxicity of trastuzumab in elderly patients with breast cancer.
Andrea Denegri ... Pietro Ameri
Journal of Geriatric Cardiology | VOL. 13
Andrea Denegri, et. al.Andrea Denegri ... Pietro Ameri
01 May 2016

More From: Breast cancer research and treatment

Paper Title
Journal
Date
Author
CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
Takumi Sato ... Kazuaki Takabe
Breast cancer research and treatment | VOL. -
Takumi Sato, et. al.Takumi Sato ... Kazuaki Takabe
17 Jul 2024
Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity promotion intervention on physical activity and patient reported outcomes in individuals with metastatic breast cancer.
Siobhan M Phillips ... William Gradishar
Breast cancer research and treatment | VOL. -
Siobhan M Phillips, et. al.Siobhan M Phillips ... William Gradishar
16 Jul 2024
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
Julia Foldi ... Lajos Pusztai
Breast cancer research and treatment | VOL. -
Julia Foldi, et. al.Julia Foldi ... Lajos Pusztai
13 Jul 2024
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Manali A Bhave ... Kevin Kalinsky
Breast cancer research and treatment | VOL. -
Manali A Bhave, et. al.Manali A Bhave ... Kevin Kalinsky
13 Jul 2024
View more papers